publication . Other literature type . Article . 1991

Intramuscular desferrioxamine in patients with Alzheimer's disease.

D MCLACHLAN;
Restricted
  • Published: 01 Jun 1991
  • Publisher: Elsevier BV
Abstract
Abstract Although epidemiological and biochemical evidence suggests that aluminium may be associated with Alzheimer's disease (AD), there is no convincing proof of a causal link for aluminium in disease progression. We have completed a two year, single-blind study to investigate whether the progression of dementia could be slowed by the trivalent ion chelator, desferrioxamine. 48 patients with probable AD were randomly assigned to receive desferrioxamine (125 mg intramuscularly twice daily, 5 days per week, for 24 months), oral placebo (lecithin), or no treatment. No significant differences in baseline measures of intelligence, memory, or speech ability existed ...
Subjects
free text keywords: General Medicine
Powered by OpenAIRE Research Graph
Any information missing or wrong?Report an Issue